Keywords: alexion, fiscal-2004, net, loss, down, pharmaceuticals, usa
Alexion's fiscal-2004 net loss down 12%
Article | 04 October 2004
Alexion Pharmaceuticals of the USA saw its revenues jump dramatically for the fiscal year ended July 31, 2004, recording sales of $4.6 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
